Quantcast

Latest Metformin Stories

2014-06-16 12:58:06

Merck Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from a post-hoc analysis showing that patients with type 2 diabetes having treatment intensified with insulin glargine therapy while also being treated with JANUVIA® (sitagliptin) 100 mg once-daily had a lower incidence of nighttime (nocturnal) hypoglycemia compared to patients also receiving placebo. Results were presented at the American Diabetes Association 74th Scientific Sessions....

2014-06-16 12:29:24

-- In a two-year study, empagliflozin as add-on to metformin demonstrated significantly greater decreases in A1C (blood glucose), body weight and blood pressure compared with glimepiride as add-on to metformin RIDGEFIELD, Conn. and INDIANAPOLIS, June 16, 2014 /PRNewswire/ -- Two phase III clinical trials studying the efficacy and safety of the investigational compound empagliflozin in type 2 diabetes (T2D) were presented today at the American Diabetes Association 74th Scientific Sessions®,...

2014-06-16 08:27:42

Up to 2.25 percentage point reduction in HbA1c achieved after only 13 weeks of dosing CARLSBAD, Calif., June 16, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today the final results from its Phase 2 study of ISIS-GCGR(Rx) in patients with type 2 diabetes uncontrolled on stable metformin therapy. In this study, patients in the per protocol population (PP) treated with ISIS-GCGR(Rx) in addition to metformin achieved absolute mean reduction in hemoglobin...

2014-06-15 15:18:02

The Endocrine Society Study suggests metformin controls blood sugar more effectively in African-Americans African Americans taking the diabetes drug metformin saw greater improvements in their blood sugar control than white individuals who were prescribed the same medication, according to a new study published in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM). An estimated 29 million Americans have diabetes. African Americans are twice as likely to...

2014-06-10 20:23:10

ROCKVILLE, Md., June 10, 2014 /PRNewswire-USNewswire/ -- Patients with type 2 diabetes who take a combination of metformin plus insulin may be at higher risk for cardiovascular disease and death compared with those who take a combination of metformin plus sulfonylurea, according to a new study funded by the Agency for Healthcare Research and Quality (AHRQ) that appears in the June 11 issue of JAMA. The study, a review of medical records from national databases, found a greater...

2014-05-27 12:27:43

Traditional Type 2 Diabetes Drug Attributes Continue to be Key Even as First-Line Treatment Paradigms Shift, According to Findings from Decision Resources Group BURLINGTON, Mass., May 27, 2014 /PRNewswire/ -- Decision Resources Group finds that Eli Lilly's insulin peglispro is set to become the clinical gold-standard in the treatment of patients with type 2 diabetes inadequately controlled with diet and exercise, when metformin is not a therapeutic option. Although metformin continues to...

2014-04-24 16:28:58

ORMD-0801 Oral Insulin Appeared Safe and Well-tolerated. No Hypoglycemic Events or Treatment Related Adverse Events Observed JERUSALEM, April 24, 2014 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today detailed results from its previously completed Phase IIa trial investigating ORMD-0801, its orally ingestible insulin capsule, in type 2...

2014-04-15 23:12:19

Avail is conducting a 6-week, Phase 2 randomized study to assess the safety, tolerability and pharmacodynamics of a new combination therapy administered to participants with type 2 diabetes mellitus. DeLand, FL (PRWEB) April 15, 2014 *To see if you qualify for this Diabetes Clinical Trial in DeLand, visit Avail Clinical Research on the web (http://www.availclinical.com) or contact us directly at (386) 785-2404. There is no cost to participate, no insurance required, and you may receive...

2014-04-08 08:30:26

--MBT Previously Reported Statistically Significant Positive Topline Results from this First Double-Blind, Randomized Clinical Trial of a Microbiome Modulator for Diabetes-- BROOMFIELD, Colo., April 8, 2014 /PRNewswire/ -- MicroBiome Therapeutics(TM) LLC, (MBT) today announced that data from the company's clinical trial of microbiome modulator NM504 in development for type 2 diabetes and prediabetes has been accepted for a Poster Preview Presentation at ICE/ENDO 2014, the joint...

2014-03-27 08:34:15

Sub-analyses Investigate the Effects of alogliptin on Cardiovascular Mortality Rates and Hospitalization for Heart Failure in Type 2 Diabetes Patients with Recent Acute Coronary Syndrome WASHINGTON and OSAKA, Japan, March 27, 2014 /PRNewswire/ -- Takeda Pharmaceutical Company Limited (Takeda) will present sub-analyses from the global EXAMINE (EXamination of CArdiovascular OutcoMes: AlogliptIN vs. Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome)...